High level MLL amplification in AML and MDS.

被引：0
|
作者：
Dolan, M [1 ]
Hirsch, B [1 ]
Eckfeldt, J [1 ]
机构：
[1] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2000年 / 114卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
55
引用
收藏
页码：315 / 315
页数：1
相关论文
共 50 条
  • [41] INFLAMMAGING VERSUS INFLAMMATION IN MDS. IS AGING A PRE-MDS STATE?
    Tofacchi, E.
    Mattiuz, G.
    Raddi, M. G.
    De Pourcq, S. J. M.
    Cassari, M.
    Amato, C.
    Consagra, A.
    Rigodanza, L.
    Bandinelli, S.
    Tanturli, M.
    Kordasti, S.
    Ferrucci, L.
    Santini, V.
    HAEMATOLOGICA, 2024, 109 : 69 - 70
  • [42] Randomized study comparing chemotherapy ±GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
    Ohm, AC
    Hast, R
    Bernell, P
    Celsing, F
    Dahl, IM
    Dybedal, I
    Lindberg, G
    Linder, O
    Löfvenberg, E
    Nilsson-Ehle, H
    Samuelsson, J
    Tangen, J
    Turesson, I
    Wallvik, J
    Winquist, I
    Öberg, G
    Björkholm, M
    Hellström-Lindberg, E
    BLOOD, 2000, 96 (11) : 148A - 148A
  • [43] Amplification of chromosome 11q.23 involving the MLL gene in a case of AML
    Michaux, L
    Wlodarska, I
    Duhem, C
    Dierlamm, J
    Ameye, G
    Dicato, M
    Verellen-Dumoulin, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 101 - 101
  • [44] Detection of elevated serum tryptase levels in MDS.
    Sperr, R
    Jordan, JH
    Stehberger, B
    Kundi, M
    Semper, H
    Kiener, H
    Horny, HP
    Geissler, K
    Wimazal, F
    Simonitsch, I
    Schwartz, LB
    Chott, A
    Lechner, K
    Valent, P
    BLOOD, 1999, 94 (10) : 287B - 287B
  • [45] Decreased platelet GPIIIb (CD36) in MDS.
    Neuwirtova, R
    Holada, K
    Karban, J
    Kvasnicka, J
    Dyr, J
    BLOOD, 1997, 90 (10) : 4047 - 4047
  • [46] A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Erba, Harry Paul
    Sobecks, Ronald
    Advani, Anjali
    Nichols, Julie
    Chan, Josephine
    Kalaycio, Matt
    BLOOD, 2006, 108 (11) : 754A - 754A
  • [47] RAS mutations in hematologically normal individuals:: A comparison with MDS.
    Padua, RA
    Larghero, J
    Taylor, C
    Warren, N
    Carter, G
    Hughes, D
    Culligan, D
    Al-Sabah, A
    Whittaker, J
    West, R
    Chomienne, C
    BLOOD, 2000, 96 (11) : 356A - 356A
  • [48] Common DNA amplification patterns is observed at mds transformation to AML: A CH-CGH study on sequential bone marrow samples at MDS diagnosis and AML evolution
    Georgiou, G.
    Zouvelou, C.
    Iakovaki, D.
    Papasava, P.
    Petrikkos, L.
    Pfeifer, D.
    Efthymiou, A.
    Panayiotidis, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 234 - 235
  • [49] Conditioning with cyclophosphamid and ATG might be sufficient for hypoplastic MDS.
    Masszi, T
    Kriván, G
    Reményi, P
    Bátai, A
    Réti, M
    BONE MARROW TRANSPLANTATION, 1999, 23 : S75 - S75
  • [50] GAB2 is a novel target of 11q amplification in AML/MDS
    Zatkova, Andrea
    Schoch, Claudia
    Speleman, Frank
    Poppe, Bruce
    Mannhalter, Christine
    Fonatsch, Christa
    Wimmer, Katharina
    GENES CHROMOSOMES & CANCER, 2006, 45 (09): : 798 - 807
12345